AstraZeneca beats top-line and bottom-line estimates; raises FY24 outlook
…
61,750€
2,07%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
AstraZeneca lifts full-year outlook on upbeat demand for therapies By Reuters
AstraZeneca lifts full-year outlook on upbeat demand for therapies…
Half-year Report
AstraZeneca
25 July 2024
H1 and Q2 2024 results
Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core…
Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Audi, Renault, Nissan Motor, AstraZeneca und Hermes
© Foto: Sven Hoppe/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im…
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups 24 View
AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of…
Lloyds, AstraZeneca, British Gas owner and more: Day ahead on Thursday
Is AstraZeneca set for another upgrade: ... read preview BT has had a tough first half according to one leading City firm,…
Tagesvorschau: Marktgeschehen am 25. Juli
Eine wahren Datenflut erwartet uns am DonnerstagHeute stehen zahlreiche Unternehmensberichte an, darunter die Halbjahreszahlen von Audi, Hermes, Roche und AstraZeneca.…
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
Sales of AstraZenecas (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new…
AstraZeneca Stock: Upgrading From Hold To Buy Ahead Of Q2 2024 Earnings
…
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
AstraZenecas (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several…